Terremoto raises $108M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 15 April, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by CNS-3D Brain Organoids Pre­dict Clin­i­cal Seizure Li­a­bil­i­ty, New Study Da­ta

SPOTLIGHT Take the Biopharma Sentiment Index survey for Q2 2026

news Beeline Medicines emerges as Bristol Myers' partner for shelved immunology drugs Terremoto raises $108M to make an 'earthquake' in small molecule space Updated: FDA asks for data on Lilly’s Foundayo to assess heart, liver risks

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

The R&D 15 is John Carroll’s annual reckoning with where biopharma’s biggest players are really investing — and where they’re not. This year he’s back at the table with some of the industry’s top research chiefs for a frank, one-hour conversation on the trends shaping drug development in 2026 and beyond. Join us.

in case you missed it 1. Replimune looks ahead as repeat CRL speeds the company's decline 2. Shedding caution, J&J makes bold claims for sales growth. Will it happen? 3. Biotech enthusiasm still high as Revolution Medicines leads $1.5B stock offering wave 4. Eli Lilly to acquire tiny Houston startup CrossBridge Bio for up to $300M 5. News Briefing Harbinger raises $100M; Astellas to close Seattle site 6. Parker Institute doubles down on cancer vaccines as part of ongoing reboot 7. FDA approves Travere's Filspari as the first drug for a rare kidney disorder 8. How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide International Consortium of Investigative Journalists 9.